Search
Exagen Inc
XGNAdd to Watchlist
4.540USD
-0.170-3.61%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
104.02MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-3.61%
5 Days
-2.16%
1 Month
-5.81%
6 Months
-24.83%
Year to Date
-25.33%
1 Year
-34.86%
Key Figures
4.690Open
4.759High
127.80KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.56%Turnover Ratio
4.710Prev. Close
4.465Low
468.23KTurnover
LossP/E Static
5.96P/B
0.00%Div Yield TTM
-43.72%ROA
12.23052wk High
1.16Volume Ratio
-15.12MNet Profit
22.91MShares
-0.8896EPS TTM
1.99Beta
-193.58%ROE
2.59052wk Low
6.24%Amplitude
58.97%Gross Margin
104.02MMarket Cap
0.99Reward/Risk
3.78%Risk Rate
TradingKey Stock Score of Exagen Inc
Currency: USD Updated: 2026-07-01Key Insights
Exagen Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 43 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.57.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Exagen Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Exagen Inc Highlights
StrengthsRisks
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.69% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 66.58M.
Undervalued
The company’s latest PE is -5.29, at a low 3-year percentile range.
Held by First Eagle Investment
Star Investor First Eagle Investment holds 75.00K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.07.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
8.571
Target Price
+80.45%
Upside Space
Exagen Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Exagen Inc Info
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Ticker SymbolXGN
CompanyExagen Inc
CEOAballi (John)
Websitehttps://exagen.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.76%
+3.40%
+1.10%
-2.09%
+3.50%Popular Instruments
53071.700
+229.200 (+0.43%)
29427.700
+116.300 (+0.40%)
7499.100
+27.600 (+0.37%)
14812.000
+9.000 (+0.06%)
69014.000
+866.000 (+1.27%)
6371.500
+18.700 (+0.29%)
68.373
+0.029 (+0.04%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4185.730
+63.820 (+1.55%)
FAQs
What is the current price of Exagen Inc (XGN)?
The current price of Exagen Inc (XGN) is 4.54.
What is the symbol of Exagen Inc?
The ticker symbol of Exagen Inc is XGN.
What is the 52-week high of Exagen Inc?
The 52-week high of Exagen Inc is 12.23.
What is the 52-week low of Exagen Inc?
The 52-week low of Exagen Inc is 2.59.
What is the market capitalization of Exagen Inc?
The market capitalization of Exagen Inc is 104.02M.
Is Exagen Inc (XGN) currently rated as Buy, Hold, or Sell?
According to analysts, Exagen Inc (XGN) has an overall rating of Buy, with a price target of 8.57.
What is the Earnings Per Share (EPS TTM) of Exagen Inc (XGN)?
The Earnings Per Share (EPS TTM) of Exagen Inc (XGN) is -0.93.